Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Huperzine A | Piracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 50-200 mcg twice daily | 1200-4800 mg/day divided into 2-3 doses |
| Timing | Morning and early afternoon. With or without food. | With or without food; split doses morning and afternoon to maintain plasma levels |
| Cycle Duration | Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment |
| Evidence Level | strong_human | moderate_human |
Potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), derived from the club moss Huperzia serrata. Exhibits preference for the tetrameric G4 form of AChE predominant in the mammalian brain. Eight-fold more potent than donepezil and two-fold more potent than rivastigmine at AChE inhibition. Crosses the BBB efficiently. Also antagonizes NMDA receptors at high concentrations and provides neuroprotection via attenuation of oxidative stress, regulation of apoptotic proteins (Bcl-2, Bax, P53, caspase-3), and upregulation of NGF.
50-200 mcg twice daily
Morning and early afternoon. With or without food.
Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →